Recent studies demonstrated phenotypic tumor suppressor activity of K-RasWT in primary mouse AML cells and in human lung and colorectal cancer cell lines and also showed that loss of KRASWT provided a fitness advantage and sensitized cells to MEK inhibition (40, 46). This evidence concerns the gene MAP2K7 and neoplasm.